Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023)
Its inclusion supports optimal B12 levels, especially in individuals using GLP-1 receptor agonists, which may deplete B12 over time
However, as with any medical treatment, potential risks and side effects should be discussed with your healthcare provider
Enhancement of nitric oxide release from nitrosyl haemoglobin and nitrosyl myoglobin by red/near infrared radiation: potential role in cardioprotection
The findings highlight that the cardioprotective effects of semaglutide may be independent of adiposity and weight loss, Laurence Sperling, a preventive cardiologist at Emory University not affiliated with the study, told Gizmodo